The KEYNOTE-158 also provides the largest sample of PD-L1-positive cervical cancer patients treated with pembrolizumab (n = 82) available to date, describing an ORR of only 14.6% (CI 7.8–24.2) [3]. This evidence concerns the gene CD274 and cervical carcinoma.